We use strictly necessary cookies to make our site work. We would also like to set optional cookies (analytical, functional and YouTube) to enhance and improve our service. You can opt-out of these cookies. By clicking “Accept All Cookies” you can agree to the use of all cookies.

Cookies Statement and Privacy Statement

Preferred Drugs

The Preferred Drugs initiative identifies a single ‘preferred drug’ within a therapeutic drug class, and offers prescribers useful guidance on selecting, prescribing and monitoring this drug for a particular condition. Prescribers are encouraged to make the preferred drug their drug of first choice when prescribing a drug from that therapeutic class.

The preferred drug is selected following a thorough evaluation of the available evidence. Factors considered in the evaluation process include, but are not limited to clinical efficacy and effectiveness (‘how well the drug works’), dosing and administration (‘how much and how often must you take the drug’), drug interactions (‘does it affect other drugs taken at the same time’), side effects, cost, national prescribing trends, and national and international clinical guidelines. A consultation period is undertaken in which submissions from interested parties, including the pharmaceutical industry and professional bodies, are accepted for consideration in the review process.

To date, a number of Preferred Drugs have been selected by the Medicines Management Programme. The Preferred Drugs and their respective therapeutic classes are detailed below:

Clinical Strategy and Programmes Division